Business of the House

Bobby Dean Excerpts

Thursday 4th December 2025 Commons Chamber

[Madam Deputy Speaker (Caroline Nokes)]

I call the Liberal Democrat spokesperson.

[Bobby Dean (Carshalton and Wallington) (LD)]

I join the Leader of the House in his tributes to Sir John Stanley and Paul Barwell. He referred to the Christmas spirit getting going in and around the House, and I ask him to spare a thought for the Lib Dem staffers clutching coffees this morning after their Christmas party last night. I cannot confirm or deny whether I joined them.

Earlier this week, the Government announced a trade deal between the US and the UK on drug prices and medicines. Having reportedly rejected a price increase of £2.5 billion earlier this summer, the Government’s negotiators went back to the table and will apparently now pay £3 billion more instead. There is a live debate over how much the NHS should pay for drugs, which I respect. Big pharma has always wanted to drive up prices and has clearly not liked the purchasing power of the NHS, but the National Institute for Health and Care Excellence thresholds have not changed for some time, and there are some who argue that that means we are missing out on particular medicines. Others make the alternative argument that the opportunity cost of that spending in other areas of healthcare means that the thresholds should stay where they are.

Wherever we stand on that debate, two things are clear. First, this considered debate should not be settled by the bully-boy tactics of President Trump. He introduced 100% tariffs, breaking the World Trade Organisation rules on tariffs over this, and has come out with the explicit intention of putting Americans first. Secondly, the Government should explain how this huge price increase will be paid for. Daniel Elkeles, the chief executive of NHS Providers, says that

“it is not yet clear how it will be paid for”,

and there are fears among GPs, dentists and community pharmacists that they will be the ones who will suffer as a result of the increase in prices. Will the Leader of the House urge a Health Minister to come to the Dispatch Box to answer questions about the impact of this new deal?

[Sir Alan Campbell]

If my memory serves me correctly, the hon. Gentleman is going to have to get used to sleepless nights; he has a few ahead of him, I think.

The hon. Gentleman raises an important matter, but the reality is that, due to the strength of our relationship with the United States, we have secured the first and best deal on pharmaceutical products—indeed, it is the lowest rate offered to any country. This deal is a win for patients and for our life sciences sector, and that is an important part of our plan for growth. Better access to innovative medicines is critical to keeping people healthy and treating illness more effectively. We are protecting the NHS and its frontline staff with record investment and reforms to deliver better care. That also means making sure that we have the best deal in place on pharmaceuticals.